RELATED ARTICLE: Major Finding: During the 5 to 10-year period of extended, continuous treatment with strontium ranelate
, postmenopausal women with osteoporosis at baseline had a 21% rate of vertebral fractures and a 14% rate of non- vertebral fractures, significantly less than the 28% and 20% rates, respectively, of fractures in a matched placebo group.
Treatment of OSteoporosis-STRATOS calismasi, postmenopozal vertebral osteoporoz tedavisinde stronsiyum ranelatin minimal etkili dozunu belirlemek amaci ile yapilmistir ve calismanin suresi 2 yil-dir.
Non hormonal - There are several medicines including drugs called bisphosphonates, parathyroid hormone and strontium ranelate
is an interesting compound being investigated in Europe.
When you put them together, they form strontium ranelate
, which is a patented drug.
New drugs and treatments are being developed all the time, although some of them are not currently available in the US, such as tibolone and oral strontium ranelate
The study population comprised the placebo groups of two randomized, controlled trials of strontium ranelate
Your medicine is strontium ranelate
(Protelos), a recommended treatment for osteoporosis.
SAN ANTONIO -- The older generation osteoporosis drug, strontium ranelate
, is receiving renewed attention as a result of a metaanalysis showing that it reduces fracture rates in postmenopausal women as well as bisphosphonates do.
The reason for this is simple: Strontium ranelate
is a drug patented by Servier Pharmaceuticals.
In the Treatment of Peripheral Osteoporosis (TROPOS) study, 5091 postmenopausal women (mean age, 77 years) with osteoporosis who were not receiving any antiosteoporosis medications were randomly assigned to receive, in double-blind fashion, 2 g per day of strontium ranelate
(680 mg per day of elemental strontium) or placebo for five years.